Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases

Ann Oncol. 2016 Jul;27(7):1354-6. doi: 10.1093/annonc/mdw148. Epub 2016 Mar 31.

Authors

O Kanai¹, K Fujita¹, M Okamura¹, K Nakatani¹, T Mio²

Affiliations

¹ Division of Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
² Division of Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan tabomio@gmail.com.

PMID: 27037297
DOI: 10.1093/annonc/mdw148

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Antibodies, Monoclonal / adverse effects*
Antineoplastic Agents / adverse effects*
Brain Neoplasms / diagnosis
Brain Neoplasms / drug therapy*
Brain Neoplasms / secondary
Carcinoma, Non-Small-Cell Lung / chemically induced
Carcinoma, Non-Small-Cell Lung / diagnosis
Carcinoma, Non-Small-Cell Lung / drug therapy*
Female
Humans
Lung Neoplasms / chemically induced
Lung Neoplasms / diagnosis
Lung Neoplasms / drug therapy*
Male
Middle Aged
Nivolumab
Severity of Illness Index*

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Nivolumab